RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test

Revvity, Inc. (RVTY) announced the receipt of the FDA’s 510(k) clearance for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. Per management, it is currently the only FDA-cleared ChLIA assay for direct quantitative measurement of free testosterone in human serum or plasma.The results on EUROIMMUN’s ChLIA platforms are expected to be rapidly available, with the first result available under an hour (in 48 minutes). It also has an estimated throughput of nearly 60 t ...